CDK 4/6 Inhibitors for ER+ Breast Cancer: Emerging Data and Future Implications

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen receptor-positive (ER+) metastatic breast cancer. One CDK 4/6 inhibitor is FDA approved and 2 others are in Phase 3 development for this use. This activity discusses the ongoing and planned clinical trials for abemaciclib and ribociclib in ER+ metastatic breast cancer, as well as the future implications for this class of agents in this patient population.

A continuing education program related to this video is offered at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7171

© 2016 Imedex, LLC.